Memic Innovative Surgery is a technology company.
Memic Innovative Surgery has raised $104.1M across 3 funding rounds.
Memic Innovative Surgery has raised $104.1M in total across 3 funding rounds.
Momentis Surgical (formerly Memic Innovative Surgery) is a medical device company founded in 2013 and headquartered in Tel Aviv, Israel, with a subsidiary in Fort Lauderdale, Florida.[1][2][7] It develops the Anovo Surgical System, a miniaturized robotic-assisted platform featuring humanoid-shaped arms with shoulder, elbow, and wrist joints, enabling surgeons to perform minimally invasive procedures like transvaginal hysterectomies, salpingectomies, oophorectomies, adnexectomies, and ovarian cyst removals.[1][2][3][4] The system serves gynecologists and hospitals by solving challenges in robotic surgery—such as high costs, large footprints, and limited access—through its small size, cost-effectiveness, unprecedented 360-degree articulation, and single-portal access, which improve patient outcomes, reduce care costs, and expand access to ambulatory surgery centers.[1][2][4]
Growth momentum includes FDA authorization as the first humanoid-armed surgical robot, first U.S. patient procedures in June 2022 at HCA Florida Kendall Hospital and Jackson Memorial Hospital, recognition on Fast Company's 2022 list of the world's 50 most innovative companies, and investment availability via platforms like OurCrowd.[2][5][6]
Momentis Surgical, originally Memic Innovative Surgery, was founded in 2013 (some sources note 2012) in Tel Aviv, Israel, by innovators focused on robotic surgery.[1][7][8] The core idea emerged from developing miniature humanoid-shaped robotic arms that mimic human shoulder, elbow, and wrist movements to enable procedures previously unimaginable with rigid systems.[3][5] Key leadership includes CEO Dvir Cohen, who in 2022 announced the rebrand to Momentis Surgical and renamed the Hominis system to Anovo, aligning the brand with an expanded mission for next-generation robotics.[1][2]
Early traction built through technological advancements, culminating in the 2022 rebrand at the Society of Robotic and Digital Surgery meeting, FDA clearance, and initial U.S. clinical use, marking a pivotal shift toward global commercialization.[1][2]
Momentis rides the explosive growth in surgical robotics, a market driven by demands for minimally invasive procedures that shorten recovery, lower costs, and improve outcomes amid rising healthcare expenses and surgeon shortages.[1][2][4] Timing is ideal post-2022 FDA clearance and U.S. debuts, capitalizing on post-pandemic shifts toward efficient, ambulatory care and single-portal technologies that address legacy systems' bulkiness and expense.[2]
Market forces like expanding robotic adoption in gynecology and beyond favor Momentis, influencing the ecosystem by democratizing access—enabling smaller facilities to offer advanced robotics—and pushing "human-touch" innovation that could extend to more indications, challenging incumbents with superior articulation and affordability.[1][4]
Momentis is poised for expansion beyond gynecology into additional surgical fields, leveraging Anovo's versatility for broader minimally invasive applications amid robotics market growth projected through cost reductions and tech maturation.[1][4] Trends like AI-enhanced dexterity, global ambulatory surgery booms, and investor interest (e.g., OurCrowd) will shape its path, potentially evolving its influence via partnerships, further FDA nods, and international scaling.[6] As a pioneer in humanoid robotics, Momentis could redefine accessible precision surgery, building on its transformative rebrand to deliver on the promise of empowering surgeons worldwide.[1][2]
Memic Innovative Surgery has raised $104.1M in total across 3 funding rounds.
Memic Innovative Surgery's investors include OurCrowd, Peregrine Ventures, chase koch, Moshe Yanai, Altair Capital Management, Cyrus Angel Fund, Rose Innovation Ltd, Tal Shaked.
Memic Innovative Surgery has raised $104.1M across 3 funding rounds. Most recently, it raised $96.0M Series D in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $96.0M Series D | OurCrowd, Peregrine Ventures, chase koch, Moshe Yanai | |
| Feb 1, 2018 | $8.0M Series C | OurCrowd, chase koch, Moshe Yanai | |
| Apr 1, 2015 | $65K Seed | Altair Capital Management, Cyrus Angel Fund, Rose Innovation Ltd, Tal Shaked |